Psychiatric Bulletin (2004) 28: 298-300. doi: 10.1192/pb.28.8.298
© 2004 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hodgson, R.
Right arrow Articles by Fryer, A. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hodgson, R.
Right arrow Articles by Fryer, A. A.
Psychiatric Bulletin (2004) 28: 298-300
© 2004 The Royal College of Psychiatrists

Service innovations

Pharmacogenetic clinics in psychiatry: a clinical reality?

*Richard Hodgson

Consultant Psychiatrist, Lyme Brook Mental Health Centre, Bradwell Hospital Site, Talke Road, Stoke-on-Trent ST57TL (tel: 01782424350; fax: 01782 425355; e-mail: richarde.hodgson{at}nsch-tr.wmids.nhs.uk)

Susan E. Smith

Senior Biomedical Scientist

Richard C. Strange

Professor of Clinical Biochemistry, Department of Clinical Biochemistry, Central Pathology Laboratory, University Hospital of North Staffordshire

Anthony A. Fryer

Principal Clinical Biochemist and Honorary Senior Lecturer, Institute of Science and Technology in Medicine, University Hospital of North Staffordshire, Stoke-on-Trent

Abstract

AIMS AND METHOD

There are few descriptions in the literature of pharmacogenetic applications in psychiatry. We describe the relevance of pharmacogenetics to clinical psychiatry using a case-note review of the first 55 patients to have their cytochrome P450 (CYP2D6) status assessed in a general psychiatry clinic.

RESULTS

The distribution of genotypes for CYP2D6 was the same as in the general population. A smaller number of reported side-effects (P=0.01) and higher medication dosages (P=0.001) were significantly associated with the extensive metabolism genotype.

CLINICAL IMPLICATIONS

This preliminary study suggests that CYP2D6 status may have an influence on medication dosage and adverse drug events reported by patients. Recommendations for further development are suggested.




eLetters:

Read all eLetters

pharmacogenetics and ethnicity
sanju george
PB Online, 9 Aug 2004 [Full text]